PALVELLA THERAPEUTICS, INC. — Form 8-K
Filed October 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Palvella announced FDA acceptance and Priority Review of its NDA for QTORIN rapamycin for microcystic lymphatic malformations, with a PDUFA target action date of February 28, 2027. The Phase 3 SELVA study achieved statistical significance across all six prespecified efficacy endpoints (p<0.001), with 95% of participants ≥6 years old showing improvement on the primary endpoint. The company is preparing for a potential standalone U.S. commercial launch in H1 2027, contingent on FDA approval.
Why this rating
FDA acceptance and Priority Review are major regulatory milestones for a clinical-stage biotech. Near-term PDUFA decision and first-in-disease potential are transformational if approved; represents ~40% of company market cap in pipeline value.
Tradability signal
NO TRADE
No trade: positive news with only -0.7% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +0.33% over 4 hrs, n=111). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $134.05 | +10 min · unknown $133.99 ▼ 0.04% | +30 min · unknown $135.81 ▲ 1.31% | +1 hr · unknown $134.44 ▲ 0.29% | +4 hrs · unknown $144.06 ▲ 7.46% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.